BLOG / 🇮🇳 India / regulatory compliance · · daily

India SEBI Regulatory Enforcement Actions — May 20, 2026

India Regulatory Enforcement Actions

By Gunpowder Editorial ·

18 high priority 18 total filings analysed

Executive Summary

The 18 filings in this stream paint a mixed picture of the Indian regulatory and corporate landscape, dominated by a handful of high-impact events.

The most significant theme is **Sammaan Capital's strategic transformation**: despite reporting a massive ₹8,101-crore net loss (driven by a ₹6,499-crore exceptional charge and portfolio repositioning), the company secured an ₹8,850-crore equity infusion from IHC and received a full sweep of credit rating upgrades (CRISIL, CARE, ICRA) to 'AA+/Stable' within 50 days, signaling a successful balance sheet cleanup. **Apollo Hospitals** shows robust full-year growth (+13.7% revenue, +15.1% PAT) but a clear sequential slowdown in Q4 (+3.2% revenue QoQ), coupled with strategic divestments of its fertility and specialty hospital chains to Kids Clinic India for ₹15,500 crore EV—a move to unlock value. **Bharti Airtel** reported a lifetime-high consolidated revenue of ₹2.11 lakh crore, but its India mobile ARPU growth was disappointing (+₹3 to ₹257), with management calling it unsatisfactory due to international roaming headwinds. **Fine Organic Industries** delivered a mixed result with Q4 PAT surging 21% YoY but full-year EBITDA declining 5.8% due to raw material cost pressures, while announcing a strategic acquisition in Malaysia. Several specialty chemical companies (DCM Shriram Fine Chemicals, Gandhar Oil, Camlin Fine Sciences) are reporting financial results for the fiscal year, with DCM showing a sharp net profit decline (from ₹1,845 Lakh to ₹429 Lakh). The period-comparison data reveals a sector-wide theme of **cost inflation and margin compression** across healthcare and chemicals, while the **capital allocation pattern** favors dividends (Apollo, DCM, Bharti, NGL Fine-Chem) and debt-raising (Sammaan up to ₹10,000 crore) over buybacks.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Board meeting · Company update · Corporate action

Tracking the trend? Catch up on the prior India SEBI Regulatory Enforcement Actions digest from May 19, 2026.

Investment Signals (12)

  • Sammaan Capital ↓ (BULLISH)
    ▲

    Full rating upgrade cycle to 'AA+/Stable' by all three agencies within 50 days of IHC's equity infusion, signal of dramatically strengthened capital position and lower cost of funds

  • Apollo Hospitals ↓ (BULLISH)
    ▲

    Full-year revenue grew 13.7% YoY and PAT 15.1% YoY, maintaining double-digit growth trajectory; EBITDA margin improved 30 bps YoY

  • Bharti Airtel ↓ (BULLISH)
    ▲

    FY2026 consolidated revenue hit a lifetime high of ₹2.11 lakh crore with EBITDAaL margin of 51.2%; India mobile revenue share reached a lifetime high

  • Fine Organic Industries ↓ (BULLISH)
    ▲

    Q4 FY26 PAT surged 58.9% QoQ and 21% YoY to ₹117.5 Cr, showing strong quarterly earnings acceleration; exports remain robust at 55% of revenue

  • Sammaan Capital ↓ (BULLISH)
    ▲

    Board approved raising up to ₹10,000 crore via debt instruments/ECBs, indicating aggressive capital raising for growth post-balance sheet cleanup

  • Fine Organic Industries ↓ (BULLISH)
    ▲

    Proposed acquisition of 80% of Oleofine Organics Sdn. Bhd., Malaysia for up to ₹83 Cr, a strategic international expansion at a likely reasonable valuation

  • Bharti Airtel ↓ (BULLISH)
    ▲

    Dividend increased 50% to ₹24 per share from ₹16, signaling strong cash flow confidence and shareholder-friendly capital allocation

  • Apollo Hospitals ↓ (BULLISH)
    ▲

    Divestment of Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India at ₹15,500 Cr EV unlocks value and sharpens focus on core hospital business

  • Sammaan Capital ↓ (BULLISH)
    ▲

    Despite massive reported loss, the underlying operating metrics show the company is clearing legacy issues; the new equity from IHC provides a clean slate for growth

  • Bharti Airtel ↓ (BULLISH)
    ▲

    Airtel Business order book grew 17% in FY2026, indicating strong enterprise demand and future revenue visibility

  • Apollo Hospitals ↓ (BULLISH)
    ▲

    Healthcare Services segment saw in-patients up 7% YoY and ARPIP up 9% YoY to ₹187,208, demonstrating strong pricing power and volume growth

  • Fine Organic Industries ↓ (BULLISH)
    ▲

    Q4 revenue grew 12.7% QoQ, suggesting a strong demand recovery despite raw material headwinds

Risk Flags (10)

  • Sammaan Capital/Financial Risk↓ [HIGH RISK]
    ▼

    Reported Q4 net loss of ₹8,101.41 Cr (EPS -₹99.10) driven by ₹6,499 Cr exceptional loss and ₹2,958 Cr impairment; full-year loss widened to ₹7,144.56 Cr from ₹1,807.46 Cr

  • DCM Shriram Fine Chemicals/Deterioration↓ [HIGH RISK]
    ▼

    Net profit fell from ₹1,845 Lakh in FY25 to ₹429 Lakh in FY26, a 77% decline; total income from operations declined 10.3% for the full year

  • Apollo Hospitals/Sequential Slowdown↓ [MODERATE RISK]
    ▼

    Q4 FY26 revenue of ₹24,385 M was only 3.2% higher than Q3, and EBITDA declined slightly QoQ (₹5,935 M vs ₹5,955 M), indicating a growth plateau

  • Fine Organic Industries/Margin Compression↓ [MODERATE RISK]
    ▼

    Full-year EBITDA declined 5.8% to ₹483 Cr despite 4.3% revenue growth, indicating significant cost pressure from raw materials and freight

  • Bharti Airtel/ARPU Stagnation↓ [MODERATE RISK]
    ▼

    India mobile ARPU rose only ₹3 to ₹257, deemed unsatisfactory by management; West Asia crisis impacting international roaming revenue

  • Apollo Hospitals/Digital Health Losses↓ [MODERATE RISK]
    ▼

    The Digital Health segment (Apollo HealthCo) posted a cash loss of ₹16 Cr in Q4 excluding ESOP charges, a continuing drag on profitability

  • DCM Shriram Fine Chemicals/Legal Issues↓ [MODERATE RISK]
    ▼

    The company reversed input tax credit of ₹229 Lakh due to withdrawal of a GST refund application, indicating regulatory complexities

  • Fine Organic Industries/Raw Material Inflation↓ [MODERATE RISK]
    ▼

    Raw material prices increased in FY26 vs FY25 and slightly in Q4 vs Q3, while freight costs also rose due to the West Asia crisis, creating margin headwinds

  • Sammaan Capital/Revenue Decline↓ [MODERATE RISK]
    ▼

    Full-year revenue from operations declined to ₹8,166 Cr from ₹8,623 Cr in FY25, showing business contraction beyond the exceptional items

  • Apollo Hospitals/Divestment Dilution↓ [LOW-MODERATE RISK]
    ▼

    The ₹15,500 Cr transaction with Kids Clinic India includes a 9.9% equity stake component, exposing Apollo to potential volatility in an associate company

Opportunities (10)

  • Sammaan Capital/Turnaround Play↓ (OPPORTUNITY)
    ◆

    With IHC's ₹8,850 Cr equity infusion, full rating upgrades to AA+/Stable, and cost of funds already declining, the company is positioned for a major operational turnaround in FY2027; valuation depressed after massive loss

  • Fine Organic Industries/International Expansion↓ (OPPORTUNITY)
    ◆

    The proposed 80% acquisition of Oleofine Organics in Malaysia for just ₹83 Cr provides a low-cost entry into ASEAN markets, leveraging Malaysia's palm oil supply chain; Q4 PAT surge shows operational momentum

  • Apollo Hospitals/Value Unlock↓ (OPPORTUNITY)
    ◆

    Divestiture of non-core fertility/specialty hospital assets at ₹15,500 Cr EV allows management to focus on core hospital business with 68% occupancy and pricing power; potential re-rating of stock

  • Bharti Airtel/ARPU Catalyst↓ (OPPORTUNITY)
    ◆

    If the West Asia crisis resolves, international roaming revenue should recover, potentially boosting ARPU by ₹5-8; management's commentary suggests a tariff hike cycle could be triggered in H2 FY2027

  • Fine Organic Industries/Demand Recovery↓ (OPPORTUNITY)
    ◆

    Q4 revenue grew 12.7% QoQ despite raw material headwinds, signaling strong end-market demand; if raw material costs stabilize, margins could expand sharply given operating leverage

  • Sammaan Capital/Debt Market Play↓ (OPPORTUNITY)
    ◆

    With AA+/Stable rating and approval to raise up to ₹10,000 Cr via debt, the company can refinance legacy high-cost debt at lower rates, improving NIMs significantly in coming quarters

  • Apollo Hospitals/Foreign Institutional Interest↓ (OPPORTUNITY)
    ◆

    Robust 18% consolidated revenue growth and 31% EBITDA growth in Q4, coupled with India's healthcare demand story, makes Apollo a strong candidate for increased FII allocation

  • Bharti Airtel/Data Monetization↓ (OPPORTUNITY)
    ◆

    With a lifetime-high India mobile revenue share and a 17% order book growth in Airtel Business, the company is well-positioned to monetize the 5G and enterprise data boom

  • DCM Shriram Fine Chemicals/Bottom Fishing↓ (OPPORTUNITY)
    ◆

    The stock may be oversold after a 77% profit decline; the company has a ₹0.40 dividend (maintained), and the Dahej leasehold land impairment reversal of ₹223 Lakh suggests asset value stabilization

  • Fine Organic Industries/Green Chemistry Premium↓ (OPPORTUNITY)
    ◆

    With over 50 years of history, 5,400+ end-users across 110 countries, and a dedicated R&D centre, the company commands a valuation premium for its ESG-compliant oleochemical portfolio

Sector Themes (6)

  • Healthcare Margin Divergence
    ◆

    Apollo Hospitals shows that while full-year EBITDA grew 13.9% YoY, Q4 saw a slight sequential decline, indicating that even in a high-growth sector like Indian healthcare, margin pressures from wage inflation and input costs are emerging at the margin. The 7% inpatient growth with 9% ARPU growth suggests pricing power is intact but volume growth is moderating.

  • Financial Services Cleanup Cycle
    ◆

    Sammaan Capital's massive exceptional loss of ₹6,499 Cr for portfolio repositioning, followed by IHC equity infusion and rating upgrades, exemplifies a broader trend of NBFCs cleaning up legacy NPAs with strategic investor backing. This pattern is likely to emerge in other stressed NBFCs, creating turnaround opportunities.

  • Specialty Chemicals Cost Crunch
    ◆

    Fine Organic Industries (FY EBITDA -5.8% despite +4.3% revenue) and DCM Shriram Fine Chemicals (profit -77% YoY) both highlight the severe margin compression in specialty chemicals due to raw material inflation (up YoY) and freight cost increases from the West Asia crisis. Companies with export exposure (55% for Fine Organic) are particularly vulnerable.

  • Telecom ARPU Stagnation Despite Revenue Growth
    ◆

    Bharti Airtel's Q4 ARPU increase of only ₹3 to ₹257, despite overall revenue growth, reflects the industry-wide challenge of converting subscriber additions into higher average realizations. The management's 'unsatisfactory' label hints that a tariff hike is likely in the coming quarters, which could be a sector-wide catalyst.

  • Corporate Restructuring to Unlock Value
    ◆

    Two major restructuring moves are visible: Apollo Hospitals divesting non-core assets (fertility, specialty hospitals) and merging Apollo Hospitals North into itself, while Sammaan Capital is repositioning its entire loan book. Both involve asset sales and structural simplification, suggesting a trend towards sharper business focus.

  • Dividend Signaling as a Confidence Metric
    ◆

    Multiple companies (Apollo ₹10/sh, Bharti ₹24/sh up from ₹16, DCM ₹0.40/sh, NGL Fine-Chem to consider dividend) are recommending or maintaining dividends despite mixed performance. This is a strong signal of management confidence in cash flows and a shareholder-friendly stance, particularly relevant in a volatile market.

Watch List (8)

  • Sammaan Capital/Earnings Call↓
    👁

    Management commentary on FY2027 growth outlook, cost of funds trajectory, and deployment of the ₹10,000 Cr debt raising plan; watch for loan book growth guidance [Scheduled: May 20-21, 2026]

  • Apollo Hospitals/AGM & Dividend↓
    👁

    Record date August 14, 2026, for ₹10/sh dividend; AGM will provide clarity on Kids Clinic India transaction timeline and merger of Apollo Hospitals North [Record Date: Aug 14, 2026; Payment: Sep 10, 2026]

  • Bharti Airtel/Airtel Africa Stake Swap↓
    👁

    The 16.3% additional stake acquisition via share swap needs regulatory approvals; watch for SEBI/RBI clearances and valuation of the swap ratio [Ongoing]

  • Fine Organic Industries/Oleofine Organics Acquisition↓
    👁

    Closure of the 80% acquisition in Malaysia for up to ₹83 Cr; due diligence and regulatory approvals in Malaysia; potential EPS accretion from H2 FY2027 [Expected Closing: H1 2026]

  • Camlin Fine Sciences/Q4 FY26 Results↓
    👁

    Board meeting on May 26, 2026, to approve results; analyst conference call at 5 PM IST on same day; watch for revenue trends and any exceptional items [May 26, 2026]

  • DCM Shriram Fine Chemicals/GST Case Outcome↓
    👁

    The withdrawal of a GST refund application and ₹229 Lakh input tax credit reversal suggests ongoing tax disputes; any adverse GST demand could impact margins further [Ongoing]

  • Bharti Airtel/Q1 FY27 ARPU Data↓
    👁

    The next quarter's ARPU will reveal whether the West Asia crisis impact is transitory or persistent; a decline below ₹250 would be a negative signal, while a rise above ₹260 would confirm recovery [Expected: Aug 2026]

  • General/SEBI Enforcement Actions on NBFCs
    👁

    Sammaan Capital's cleanup may prompt SEBI to scrutinize other NBFCs with large NPAs; watch for any show-cause notices to other housing finance companies that could trigger similar portfolio repositioning [Ongoing]

Filing Analyses (18)
Apollo Hospitals Enterprise Limited Board Meeting mixed materiality 9/10

20-05-2026

Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in the prior year, and profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, the board also approved a transaction to divest its stake in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited at an enterprise value of approximately ₹15,500 million, and approved the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company. A final dividend of ₹10 per share (200% of face value) was recommended.

  • · The board declared that the statutory auditors have issued audit reports with unmodified opinion on the financial statements.
  • · The record date for the final dividend and AGM is fixed as August 14, 2026.
  • · The dividend, if approved, will be paid on or before September 10, 2026.
  • · Dr. Prathap C Reddy was re-appointed as Executive Chairman for two years from June 25, 2026, subject to shareholder approval.
  • · Ms. Rama Bijapurkar was re-appointed as Independent Director for a second term of five years from November 12, 2026 to November 11, 2031, subject to shareholder approval by special resolution.
  • · The company's credit ratings are AAA (ICRA Ltd) and AA+ (Crisil Ltd).
  • · No borrowings were made by way of issuance of debt securities during the year.
  • · The standalone balance sheet shows total assets of ₹149,144 million as of March 31, 2026, up from ₹133,723 million a year earlier.
  • · Net cash generated from operating activities was ₹20,591 million for FY2025-26, compared to ₹17,419 million in the prior year.
Fine Organic Industries Limited Regulatory Action neutral materiality 4/10

20-05-2026

Fine Organic Industries Limited released its May 2026 investor presentation, highlighting its position as a leading global producer of oleochemical-based specialty additives for foods, polymers, feeds, cosmetics, and coatings. The company reported a workforce of 930+ employees, serves over 5,400 end-users across 110+ countries, and emphasizes green chemistry and sustainability. However, the filing does not include any financial performance data, period-over-period comparisons, or specific growth metrics, limiting the ability to assess current business trends.

  • · The company has over 50 years of history, starting as a partnership firm in 1970 and incorporating as Fine Organic Industries in 1973.
  • · R&D centre established in Navi Mumbai (2008-2012) and a dedicated R&D centre (Fine Research & Development Centre Pvt. Ltd.) commissioned in 2014-2015.
  • · Wholly owned subsidiaries: Fine Organics Americas LLC (USA), Fine Organics FZE (UAE), Fine Europe (Mumbai) Pvt. Ltd., and Fine Specialty Surfactants Pvt. Ltd.
  • · Joint venture in Thailand (JVC) commenced production in 2022-2026.
  • · Women employees constitute 19% of the workforce; over 10% of employees have completed more than 25 years; over 9% are second-generation employees.
  • · The company has fully automated production facilities and multiple production sites.
  • · Board includes 11 directors, with Shailendra Nadkarni appointed as Independent Director effective May 19, 2026 (subject to shareholder approval).
NGL Fine-Chem Limited Regulatory Action neutral materiality 4/10

20-05-2026

NGL Fine-Chem Limited has informed the stock exchanges that its Board of Directors, scheduled to meet on May 21, 2026, will consider and recommend a final dividend for FY2025-26, in addition to approving audited financial results and fixing AGM-related dates. The trading window remains closed until May 23, 2026, per insider trading regulations.

  • · Board meeting scheduled for May 21, 2026, to consider audited consolidated and standalone financial results for Q4 and FY ended March 31, 2026.
  • · Board will also fix the date of the Annual General Meeting (AGM), book closure, and record date for AGM and e-voting.
  • · Trading window closed from April 1, 2026, and will remain closed until 48 hours after the results declaration (May 23, 2026).
Finelistings Technologies Limited Regulatory Action neutral materiality 3/10

20-05-2026

Finelistings Technologies Limited has informed BSE that a Board Meeting will be held on May 28, 2026, to consider and approve the audited financial results for the half year and year ended March 31, 2026. The meeting will take place at the company's registered office in New Delhi. No financial figures or performance comparisons are provided in this filing.

  • · Board Meeting scheduled for Thursday, 28th May 2026 at 4:00 PM IST.
  • · Meeting location: Office 507, 5th Floor, Eros Corporate Tower, Nehru Place, South Delhi, New Delhi, India, 110019.
  • · Agenda includes approval of Audited Financial Results for Half Year and Year ended 31st March 2026 along with Auditor's Report.
  • · Company CIN: L74999DL2018PLC331504; Security ID: FTL / Code: 544173.
Sammaan Capital Limited Company Update positive materiality 8/10

20-05-2026

ICRA, an affiliate of Moody's, upgraded Sammaan Capital Limited's long-term debt rating to 'ICRA AA+/Stable' and removed it from 'Rating Watch with Developing Implications'. This completes a full upgrade cycle by all three domestic rating agencies (CRISIL, CARE, ICRA) within 50 days of IHC's equity infusion on March 31, 2026, reflecting strengthened capital position and strategic support from IHC. The company expects the upward rating trajectory to improve international ratings and has already seen a meaningful reduction in cost of funds, enabling more competitive pricing and accelerated disbursals.

  • · CRISIL upgraded the Company's ratings to 'CRISIL AA+/Stable' on April 9, 2026.
  • · CARE Ratings upgraded the Company's ratings to 'CARE AA+; Stable' on May 12, 2026.
  • · ICRA completed its upgrade to '[ICRA]AA+/Stable' on May 20, 2026.
  • · IHC's investment in the Company occurred on March 31, 2026.
  • · The Company expects positive movement on international ratings in the coming quarters.
  • · The sequential rating upgrades have already translated into a meaningful improvement in the Company's cost of funds.
Gandhar Oil Refinery (India) Limited Regulatory Action neutral materiality 3/10

20-05-2026

Gandhar Oil Refinery (India) Limited has informed the stock exchanges that its Board of Directors will meet on May 26, 2026, to consider and approve the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The trading window for designated persons and their relatives remains closed until 48 hours after the outcome of the meeting.

  • · Board meeting scheduled for May 26, 2026.
  • · Agenda includes approval of audited financial results for Q4 and FY ended March 31, 2026.
  • · Trading window closed from April 1, 2026, and will remain closed until 48 hours after the board meeting outcome.
  • · Notice of the meeting is uploaded on the company's website at https://gandharoil.com/investor-relations/intimations-outcome-of-board-meeting.
Sammaan Capital Limited Board Meeting mixed materiality 9/10

20-05-2026

For the quarter ended March 31, 2026, Sammaan Capital reported a net loss of ₹8,101.41 crore (EPS -₹99.10) from a total income of ₹1,361.32 crore, compared to a profit of ₹324.04 crore in the same quarter last year. The massive loss was driven by exceptional items of ₹6,499.17 crore and an impairment charge of ₹2,958.08 crore, reflecting a strategic portfolio repositioning. Full year net loss widened to ₹7,144.56 crore from ₹1,807.46 crore in FY25, while revenue from operations declined to ₹8,166.16 crore from ₹8,623.33 crore. However, the company raised ₹8,850 crore through a preferential issue from IHC, received multiple credit rating upgrades (CRISIL AA+/Stable, CARE AA+/Stable), and the Board approved raising up to ₹10,000 crore via debt instruments.

  • · Audit reports issued with unmodified opinion on standalone and consolidated financial statements.
  • · No deviation or variation in utilisation of proceeds from issue of equity shares and NCDs during Q4 FY26.
  • · Security cover certificate for Q4 FY26 filed under Regulation 54.
  • · Joint Statutory Auditors issued unmodified audit reports.
  • · Moody's upgraded long-term CFR to B1 with positive outlook.
  • · CRISIL upgraded rating to CRISIL AA+/Stable.
  • · CARE upgraded long-term debt to CARE AA+/Stable, CP reaffirmed at CARE A1+, perpetual debt upgraded to CARE AA/Stable.
  • · Net gain on fair value changes doubled YoY in FY26 (₹969.33 Cr vs ₹535.60 Cr).
  • · Impairment on financial instruments in FY26 declined to ₹3,627.94 Cr from ₹5,068.50 Cr YoY, but Q4 FY26 saw a massive spike.
  • · Share capital increased from ₹162.70 Cr to ₹228.76 Cr due to preferential allotment.
  • · Basic EPS for FY26: -₹87.72 (vs -₹26.70 in FY25); Diluted EPS: -₹87.72 (vs -₹26.70).
Apollo Hospitals Enterprise Limited Agm/Egm mixed materiality 9/10

20-05-2026

Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in FY2024-25, and net profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million was only 3.2% higher than the preceding quarter (₹23,637 million), and EBITDA for the quarter was ₹5,935 million versus ₹5,955 million in Q3 FY2026, indicating a slight sequential decline. The Board recommended a final dividend of ₹10 per share (200% of face value ₹5), approved the re-appointment of Dr. Prathap C Reddy as Executive Chairman for two more years, and approved a transaction to divest stakes in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited for an enterprise value of approximately ₹15,500 million (₹7,650 million cash + 9.9% equity stake).

  • · Standalone EBITDA for FY2025-26 was ₹23,280 million, up from ₹20,442 million in FY2024-25 (13.9% YoY growth).
  • · Standalone total comprehensive income for FY2025-26 was ₹14,810 million, up from ₹12,965 million in FY2024-25.
  • · Standalone basic EPS for FY2025-26 was ₹103.81, compared to ₹90.15 in FY2024-25.
  • · Standalone borrowings (non-current + current) increased from ₹17,832.2 million at March 31, 2025 to ₹18,222.2 million at March 31, 2026.
  • · The Board approved the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company via NCLT route.
  • · The company's credit ratings: ICRA AAA and Crisil AA+.
  • · No debt securities were issued during the year.
  • · The AGM is scheduled for August 25, 2026 via video conferencing; record date for dividend and AGM is August 14, 2026; dividend payment on or before September 10, 2026.
Sammaan Capital Limited Result negative materiality 9/10

20-05-2026

Sammaan Capital Limited (formerly Indiabulls Housing Finance) reported audited consolidated financial results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion. The results include a significant exceptional loss of ₹6,499.17 crore and other comprehensive loss of ₹652.78 crore due to a change in business model for a pool of loan exposures and sale to an ARC. The Board also approved an enabling resolution to raise up to ₹10,000 crore through debt instruments or ECBs.

  • · Audited standalone and consolidated financial results for quarter and year ended March 31, 2026, with unmodified audit opinion.
  • · Board meeting held on May 20, 2026, commenced at 2:00 PM and concluded at 3:30 PM.
  • · No deviation or variation in utilization of proceeds from issue of equity shares and non-convertible debentures during the quarter.
  • · Certificate of Security Cover for the quarter ended March 31, 2026, filed pursuant to Regulation 54.
  • · Management overlay recognized over and above ECL provision, approved by Board on March 30, 2026 and May 15, 2026.
DCM Shriram Fine Chemicals Ltd Regulatory Action negative materiality 8/10

20-05-2026

DCM Shriram Fine Chemicals Ltd reported a net loss of ₹408 Lakh for Q4 FY26, compared to a profit of ₹427 Lakh in Q4 FY25, while full-year net profit fell sharply to ₹429 Lakh from ₹1,845 Lakh in FY25. Total income from operations declined 17.8% YoY in Q4 and 10.3% for the full year. The results reflect the impact of a composite scheme of arrangement that became effective in December 2025, which included the transfer of net assets and the issuance of new equity shares.

  • · The Board recommended a final dividend of ₹0.40 per equity share (face value ₹2 each) for FY26, subject to shareholder approval.
  • · The Company reversed an excess impairment loss of ₹223 Lakh on leasehold land in Dahej, Gujarat, and also reversed input tax credit of ₹229.02 Lakh due to withdrawal of a GST refund application.
  • · The Company assessed the new Labour Codes and concluded there is no material financial impact based on existing remuneration structure.
  • · The Scheme of Arrangement resulted in Daurala Foods and Beverages Private Limited becoming a wholly owned subsidiary of the Company.
  • · The Company's business is a single primary segment: manufacturing of Organics and fine chemicals in India.
Apollo Hospitals Enterprise Limited Corp. Action mixed materiality 9/10

20-05-2026

Apollo Hospitals Enterprise reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in FY2024-25, and net profit of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million was only 3.2% higher than the preceding quarter's ₹23,637 million, and EBITDA margin declined sequentially. The Board recommended a final dividend of ₹10 per share (200% of face value ₹5), approved the divestment of Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India for an enterprise value of ₹15,500 million, and approved the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company.

  • · EBITDA for FY2025-26 was ₹23,280 million, up from ₹20,442 million in FY2024-25.
  • · Q4 FY2026 EBITDA was ₹5,935 million, compared to ₹5,955 million in Q3 FY2026 (flat).
  • · Total standalone income for FY2025-26 was ₹96,980 million, up from ₹85,498 million.
  • · Finance costs for FY2025-26 were ₹2,417 million, down from ₹2,540 million in FY2024-25.
  • · The company's credit rating is AAA from ICRA and AA+ from Crisil.
  • · Record date for dividend and AGM is August 14, 2026; AGM on August 25, 2026; dividend payment by September 10, 2026.
  • · Re-appointment of Dr. Prathap C Reddy as Executive Chairman for two years from June 25, 2026, subject to shareholder approval.
  • · Re-appointment of Ms. Rama Bijapurkar as Independent Director for second term from November 12, 2026 to November 11, 2031, subject to special resolution.
  • · Merger of Apollo Hospitals North Ltd into the company subject to NCLT and other approvals.
  • · No debt securities issued during the year.
Apollo Hospitals Enterprise Limited Company Update mixed materiality 9/10

20-05-2026

Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹93,262 million for FY2025-26, up 13.7% from ₹82,021 million in FY2024-25, and profit after tax of ₹14,926 million, up 15.1% from ₹12,963 million. However, Q4 FY2026 revenue of ₹24,385 million was only 3.2% higher than the preceding quarter's ₹23,637 million, indicating a slowdown. The Board recommended a final dividend of ₹10 per share (200% of face value ₹5) and approved the divestment of subsidiaries Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India for an enterprise value of ₹15,500 million, as well as the merger of wholly owned subsidiary Apollo Hospitals North Ltd into the company.

  • · Standalone EBITDA for FY2025-26 was ₹23,280 million, up from ₹20,442 million in FY2024-25.
  • · Standalone total income for FY2025-26 was ₹96,980 million, up from ₹85,498 million.
  • · Standalone total expenses for FY2025-26 were ₹77,403 million, up from ₹68,613 million.
  • · Standalone finance costs for FY2025-26 were ₹2,417 million, down from ₹2,540 million.
  • · Standalone other income for FY2025-26 was ₹3,718 million, up from ₹3,477 million.
  • · The Board approved re-appointment of Dr. Prathap C Reddy as Executive Chairman for two years from June 25, 2026.
  • · The Board approved re-appointment of Ms. Rama Bijapurkar as Independent Director for a second term of five years from November 12, 2026 to November 11, 2031.
  • · Record date for dividend and AGM is August 14, 2026; AGM on August 25, 2026; dividend payment on or before September 10, 2026.
  • · Credit rating: AAA by ICRA Ltd and AA+ by Crisil Ltd.
  • · No borrowings by way of issuance of debt securities during the year.
Apollo Hospitals Enterprise Limited Company Update mixed materiality 8/10

20-05-2026

Apollo Hospitals Enterprise Limited reported consolidated revenue of ₹66,055 Mio for Q4 FY26, up 18% YoY, and EBITDA of ₹10,109 Mio (15.3% margin), up 31% YoY. However, the Digital Health segment (Apollo HealthCo) posted a cash loss of ₹16 Cr for the quarter (excluding ESOP charges), and the Online Pharmacy Distribution segment reported an EBITDA loss of ₹391 Mio vs. a loss of ₹1,253 Mio in Q4 FY25. Overall PAT grew 36% YoY to ₹5,292 Mio, but Healthcare Services PAT growth was only 7% due to tax reversals in the prior year.

  • · Healthcare Services segment reported 156,728 in-patients in Q4 FY26, up 7% YoY.
  • · Average Revenue per In-patient (ARPIP) was ₹187,208, up 9% YoY.
  • · Overall occupancy was 68%, with established units at 69%.
  • · Apollo 24|7 had 47 Mn+ registered users and ~9 Lacs daily active users.
  • · Offline Pharmacy Distribution operated 7,289 stores as of March 31, 2026.
  • · Online Pharmacy Distribution EBITDA loss narrowed to ₹391 Mio from ₹1,253 Mio in Q4 FY25.
  • · AHLL's Mother & Child and Fertility businesses valued at INR 1,550 Crore in a combination of cash and 9.9% equity stake in the combined entity (subject to CII approval).
  • · AHLL operates 316 clinics, 2,501 diagnostics centers, 167 dialysis centers, and 280 dental centers.
  • · Consolidated revenue for FY26 was ₹252,285 Mio (up 16% YoY), EBITDA ₹37,693 Mio (up 25% YoY), PAT ₹19,415 Mio (up 34% YoY).
  • · Healthcare Services PAT growth of 7% in Q4 FY26 was impacted by tax reversals/adjustments in Q4 FY25.
Bharti Airtel Limited Company Update mixed materiality 9/10

20-05-2026

Bharti Airtel reported consolidated revenue of ~₹2,11,000 Crore for FY2026, a lifetime high, with EBITDAaL of ~₹1,08,000 Crore (margin 51.2%). Q4 FY2026 consolidated revenue was ~₹55,400 Crore, up 2.6% sequentially, but India mobile ARPU rose only ₹3 to ₹257, which management called unsatisfactory partly due to the West Asia crisis impacting international roaming. The Board approved a share swap to acquire an additional 16.3% stake in Airtel Africa, and recommended a dividend of ₹24 per share (up from ₹16).

  • · Africa accounts for 29% of consolidated revenues.
  • · India mobile revenue share reached a lifetime high.
  • · Airtel Business order book grew 17% in FY2026.
  • · Digital businesses revenue grew 27% in FY2026.
  • · Net debt to EBITDAaL improved to 1.1x.
  • · Board approved a share swap to acquire additional 16.3% in Airtel Africa (no cash deal).
  • · Geopolitical crisis impacting international roaming, capex due to INR depreciation, and energy prices.
  • · Women workforce representation improved from 11% in 2023 to over 20%.
  • · Airtel Money received RBI approval to operate as an NBFC (non-deposit taking).
  • · Nxtra announced a $1 billion fund raise from marquee investors.
  • · Airtel Cloud secured 24 deals in FY2026 with additional wins in April.
Fine Organic Industries Limited Regulatory Action mixed materiality 8/10

20-05-2026

Fine Organic Industries reported Q4 FY26 revenue of ₹625.3 Cr (+3.1% YoY, +12.7% QoQ) and PAT of ₹117.5 Cr (+21.0% YoY, +58.9% QoQ). For FY26, revenue grew 4.3% YoY to ₹2,365.8 Cr, but EBITDA declined 5.8% to ₹483.0 Cr and PAT rose only 1.6% to ₹417.1 Cr (including a ₹6.98 Cr insurance claim). The company announced a proposed acquisition of 80% of Oleofine Organics Sdn. Bhd., Malaysia for up to RM 34.210 million (~₹83 Cr), and incorporated subsidiaries in the US, UAE, and Thailand.

  • · Exports accounted for ~55% of total revenue in Q4 FY26 and FY26; domestic demand 45%.
  • · Raw material prices increased in FY26 vs FY25 and slightly in Q4FY26 vs Q3FY26.
  • · Freight costs stabilized during the year but increased in Q4FY26 due to West Asia crisis.
  • · The company made an incremental gratuity provision of ₹7.11 Cr for the quarter and nine months ended Dec 31, 2025 due to new Labour Code.
  • · The proposed acquisition of Oleofine Organics Sdn. Bhd. is for up to 80% shares, aggregating up to RM 34.210 million (~₹83 Cr).
  • · Equity investment in Fine Organics Americas LLC: USD 1.12 million (~₹9.6 Cr) for 160 acres in South Carolina.
  • · Preference shares issued to WOS Fine Organic Industries (SEZ) Pvt. Ltd.: ₹65 Cr.
  • · Equity infused in JV in Thailand: THB 22.50 million (~₹6.17 Cr).
  • · Equity infused in Fine Organics FZE, Dubai: AED 200,000 (~₹49.48 L).
  • · FY26 PAT includes a ₹6.98 Cr insurance claim for business interruption.
Camlin Fine Sciences Limited Regulatory Action neutral materiality 5/10

20-05-2026

Camlin Fine Sciences Limited has informed the stock exchanges that its Board of Directors will meet on May 26, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window for dealing in the company's equity shares remains closed from April 1, 2026, until 48 hours after the financial results are made public.

  • · Board meeting scheduled for Tuesday, May 26, 2026
  • · Agenda includes approval of audited standalone and consolidated financial results for Q4 FY26 and full year FY26
  • · Trading window has been closed since April 1, 2026, and will reopen 48 hours after the results are made public
  • · Filing made under Regulation 29 of SEBI (LODR) Regulations, 2015
Camlin Fine Sciences Limited Regulatory Action neutral materiality 2/10

20-05-2026

Camlin Fine Sciences Limited has announced a conference call for investors and analysts on May 26, 2026, to discuss its audited financial results for the quarter and year ended March 31, 2026. The call will be led by senior management including the Chairman & Managing Director, Managing Director, and CFO. The filing contains no financial data or performance metrics.

  • · The conference call is scheduled for Tuesday, May 26, 2026 at 5:00 PM IST.
  • · Pre-registration is required via a provided link.
  • · Dial-in numbers are provided for India, USA, UK, Singapore, and Hong Kong.
  • · The company states that no unpublished price-sensitive information (UPSI) will be discussed.
  • · The date of the call is subject to change due to exigencies.
Gennex Laboratories Ltd Regulatory Action neutral materiality 3/10

20-05-2026

Gennex Laboratories Ltd has submitted newspaper publications to stock exchanges regarding a Board Meeting scheduled for May 30, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The notices were published in Business Standard (English) and Saksham (Telugu local) on May 20, 2026. No financial results or performance data are included in this filing.

  • · Board meeting scheduled for Saturday, May 30, 2026 at the corporate office in Hyderabad.
  • · Meeting agenda includes adoption of audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, along with statutory auditors' reports.
  • · Newspaper notices published in Business Standard (English) and Saksham (Telugu local) on May 20, 2026.
  • · The notice is also available on the company's website and BSE website.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 18 filings

Start free trial Browse all digests

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: India SEBI Regulatory Enforcement Actions

May 27, 2026

India SEBI Regulatory Enforcement Actions — May 27, 2026

May 26, 2026

India SEBI Regulatory Enforcement Actions — May 26, 2026

May 25, 2026

India SEBI Regulatory Enforcement Actions — May 25, 2026

May 24, 2026

India SEBI Regulatory Enforcement Actions — May 24, 2026

🇮🇳 More from India

View all →

May 28, 2026

India Pre-Market Regulatory Roundup — May 28, 2026

India Pre-Market Regulatory Roundup

May 28, 2026

India Quarterly Results BSE NSE Announcements — May 28, 2026

India Quarterly Results BSE NSE Announcements

May 28, 2026

India Upcoming Corporate Actions BSE NSE — May 28, 2026

India Upcoming Corporate Actions BSE NSE

May 27, 2026

India Pre-Market Regulatory Roundup — May 27, 2026

India Pre-Market Regulatory Roundup
← All India digests